Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMRADYL)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Pinacidilum; P 1134; S 1230; P-154; Pinacidil (anhydrous); Pinacidilum [INN-Latin]; S-1230; N-Cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)guanidine; Guanidine, 2-cyano-3-(4-pyridyl)-1-(1,2,2-trimethylpropyl)-, monohydrate; Guanidine, N-cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)-, monohydrate; (+-)-Pinacidil; (+/-)-N-Cyano-N'-4-pyridinyl-N"-(1,2,2-trimethylpropyl)guanidine; (R,S)-Pinacidil; (inverted question mark)-N-Cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)-guanidine; 1-cyano-2-(3,3-dimethylbutan-2-yl)-3-pyridin-4-ylguanidine; 2-Cyano-3-(4-pyridinyl)-1-(1,2,2-trimethylpropyl)guanidine; 2-Cyano-3-(4-pyridyl)-1-(1,2,2-trimethylpropyl)guanidine monohydrate
| |||||
| Therapeutic Class | Antihypertensive Agents | |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Bone
Osteosarcoma
Breast
Breast adenocarcinoma
Breast epithelium
Normal
Cervix
Cervical adenocarcinoma
Colon
Colorectal adenocarcinoma
Hematopoietic system
Normal
Kidney
Normal (Immortalized)
Normal (Transformed)
Liver
Hepatoblastoma
Hepatocellular carcinoma
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Pancreas
Pancreatic carcinoma
Peripheral blood
Acute monocytic leukemia
T-cell acute lymphoblastic leukemia
Prostate
Prostate carcinoma
Skin
Melanoma
Umbilical vein
Normal
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
